CD69 Antikörper (CD69) (PE)

Details for Product anti-CD69 Antibody No. ABIN302038, Anbieter: Anmelden zum Anzeigen
Antigen
  • 5830438K24Rik
  • AI452015
  • AIM
  • VEA
  • BL-AC/P26
  • CLEC2C
  • EA1
  • GP32/28
  • MLR-3
  • Cd69 molecule
  • CD69 antigen
  • CD69 molecule
  • Cd69
  • CD69
Reaktivität
Human
268
190
37
8
7
7
5
4
4
2
1
1
1
Wirt
Maus
194
109
80
24
18
4
Klonalität (Klon)
Monoklonal ()
Konjugat
Dieser CD69 Antikörper ist konjugiert mit PE
50
43
26
24
12
11
10
9
7
7
7
6
5
5
5
5
4
4
4
4
3
3
3
3
3
3
2
2
2
2
1
1
1
1
1
1
1
1
1
Applikation
Flow Cytometry (FACS), Functional Studies (Func), Immunohistochemistry (Formalin-fixed Sections) (IHC (f))
318
113
105
54
51
48
40
23
16
13
9
7
5
4
3
3
3
2
2
2
2
1
1
1
1
Optionen
Hersteller
Anmelden zum Anzeigen
Hersteller Produkt- Nr.
Anmelden zum Anzeigen
Immunogen anti-µ,-stimulated human B lymphocytes
Klon FN50
Isotyp IgG1
Spezifität The antibody FN50 recognizes CD69, an lymphocyte early activation marker.
HLDA IV, WS Code A 91
Produktmerkmale The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
Andere Bezeichnung CD69 (CD69 Antibody Abstract)
Hintergrund CD69 (C-type lectin domain family 2 C, CLEC2C, also known as AIM) is one of the earliest inducible cell surface molecules acquired during leukocyte activation. This glycoprotein serves as a lectin-type receptor in lymphocytes, NK cells and platelets, it is involved in lymphocyte proliferation. CD69 expression is counteracted on T cells in the AIDS stage of HIV infection, and may be also predictive for clinical response to chemoimmunotherapy.
Applikations-hinweise The reagent is designed for Flow Cytometry analysis of human blood cells using 20 μ,l reagent / 100 μ,l of whole blood or 106 cells in a suspension.The content of a vial (2 ml) is sufficient for 100 tests.
Beschränkungen Nur für Forschungszwecke einsetzbar
Rekonstitution No reconstitution is necessary.
Buffer The reagent is provided in phosphate buffered saline (PBS) containing 15 mM sodium azide and 0.2 % (w/v) high-grade protease free Bovine Serum Albumin (BSA) as a stabilizing agent.
Konservierungs-mittel Sodium azide
Vorsichtsmaßnahmen This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung Do not freeze.
Avoid prolonged exposure to light.
Lagerung 4 °C
Informationen zur Lagerung Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Bilder des Herstellers
Flow Cytometry (FACS) image for anti-CD69 (CD69) antibody (PE) (ABIN302038) Surface staining of human peripheral blood using anti-CD69 antibody (clone FN50) afte...
Produkt verwendet in: Hrdinka, Dráber, Stepánek, Ormsby, Otáhal, Angelisová, Brdicka, Paces, Horejsí, Drbal: "PRR7 is a transmembrane adaptor protein expressed in activated T cells involved in regulation of T cell receptor signaling and apoptosis." in: The Journal of biological chemistry, Vol. 286, Issue 22, pp. 19617-29, 2011 (PubMed).

Drbal, Moertelmaier, Holzhauser, Muhammad, Fuertbauer, Howorka, Hinterberger, Stockinger, Schütz: "Single-molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement." in: International immunology, Vol. 19, Issue 5, pp. 675-84, 2007 (PubMed).

Tomescu, Chehimi, Maino, Montaner: "NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 179, Issue 4, pp. 2097-104, 2007 (PubMed).

Allgemeine Veröffentlichungen Pitsios, Dimitrakopoulou, Tsalimalma, Kordossis, Choremi-Papadopoulou: "Expression of CD69 on T-cell subsets in HIV-1 disease." in: Scandinavian journal of clinical and laboratory investigation, Vol. 68, Issue 3, pp. 233-41, 2008 (PubMed).

Konjevi?, Jovi?, Vuleti?, Radulovi?, Jeli?, Spuzi?: "CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma." in: European journal of clinical investigation, Vol. 37, Issue 11, pp. 887-96, 2007 (PubMed).